TWI887192B - 拮抗腫瘤細胞中wnt訊息傳導之多肽 - Google Patents

拮抗腫瘤細胞中wnt訊息傳導之多肽 Download PDF

Info

Publication number
TWI887192B
TWI887192B TW107118382A TW107118382A TWI887192B TW I887192 B TWI887192 B TW I887192B TW 107118382 A TW107118382 A TW 107118382A TW 107118382 A TW107118382 A TW 107118382A TW I887192 B TWI887192 B TW I887192B
Authority
TW
Taiwan
Prior art keywords
isvd
seq
lrp5
binding
polypeptide
Prior art date
Application number
TW107118382A
Other languages
English (en)
Chinese (zh)
Other versions
TW201906858A (zh
Inventor
維托利亞 辛薩拉
克勞斯 彼得 坤克勒
馬利 安卓 拜司
凱倫 克蘿蜜
史戴芬妮 史戴倫斯
畢翠斯 史特勞勃
Original Assignee
比利時商艾伯林克斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59021278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI887192(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 比利時商艾伯林克斯公司 filed Critical 比利時商艾伯林克斯公司
Publication of TW201906858A publication Critical patent/TW201906858A/zh
Application granted granted Critical
Publication of TWI887192B publication Critical patent/TWI887192B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04Dimeric indole alkaloids, e.g. vincaleucoblastine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW107118382A 2017-05-31 2018-05-30 拮抗腫瘤細胞中wnt訊息傳導之多肽 TWI887192B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17173782 2017-05-31
EP17173782.8 2017-05-31
??17173782.8 2017-05-31

Publications (2)

Publication Number Publication Date
TW201906858A TW201906858A (zh) 2019-02-16
TWI887192B true TWI887192B (zh) 2025-06-21

Family

ID=59021278

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107118382A TWI887192B (zh) 2017-05-31 2018-05-30 拮抗腫瘤細胞中wnt訊息傳導之多肽

Country Status (25)

Country Link
US (3) US11033636B2 (enExample)
EP (1) EP3630816B1 (enExample)
JP (1) JP7216024B2 (enExample)
KR (1) KR102717656B1 (enExample)
CN (1) CN110637030B (enExample)
AR (1) AR111840A1 (enExample)
AU (1) AU2018276409B2 (enExample)
BR (1) BR112019022729A2 (enExample)
CA (1) CA3060401A1 (enExample)
CL (1) CL2019003419A1 (enExample)
CO (1) CO2019012329A2 (enExample)
EA (1) EA201992808A1 (enExample)
ES (1) ES2979194T3 (enExample)
HU (1) HUE067691T2 (enExample)
IL (1) IL270854B2 (enExample)
MA (1) MA48760A (enExample)
MX (1) MX2019014331A (enExample)
MY (1) MY200744A (enExample)
PE (1) PE20200610A1 (enExample)
PH (1) PH12019502602A1 (enExample)
PL (1) PL3630816T3 (enExample)
TW (1) TWI887192B (enExample)
UA (1) UA125761C2 (enExample)
WO (1) WO2018220080A1 (enExample)
ZA (1) ZA201906610B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA48760A (fr) * 2017-05-31 2020-04-08 Boehringer Ingelheim Int Polypeptides ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales
JP2020530454A (ja) 2017-08-07 2020-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 安全な細胞治療薬を生成するためのプラットフォーム
AU2018393073B2 (en) 2017-12-19 2025-09-18 Surrozen Operating, Inc. Wnt surrogate molecules and uses thereof
CA3085785A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-lrp5/6 antibodies and methods of use
CN117946267A (zh) 2017-12-19 2024-04-30 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
WO2020080941A1 (en) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
EP3924381A4 (en) * 2019-02-11 2023-07-26 Surrozen Operating, Inc. MODULATION OF WNT SIGNALING IN EYE DISEASES
CN113646048A (zh) * 2019-03-29 2021-11-12 勃林格殷格翰国际有限公司 抗癌组合疗法
CA3147827A1 (en) * 2019-08-14 2021-02-18 Modmab Therapeutics Inc. Antibodies that bind to lrp5 proteins and methods of use
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
KR20230011226A (ko) * 2021-07-13 2023-01-20 인제대학교 산학협력단 NEURL 유전자, 이를 포함하는 발현벡터 또는 NEURL 단백질을 유효성분으로 포함하는 β-카테닌 과발현으로 인한 암질환 예방 또는 치료용 약학조성물
CN117897408A (zh) * 2021-08-10 2024-04-16 热生物制品有限公司 新型tim-4结合剂的生成和表征
CN114702588B (zh) * 2022-04-27 2022-11-22 博际生物医药科技(杭州)有限公司 抗Nectin-4抗体和双特异性抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017085172A2 (en) * 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2285767T3 (es) 1997-04-15 2007-11-16 MERCK & CO., INC. Receptor de ldl.
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
EP1395285A4 (en) 2001-05-17 2005-06-01 Genome Therapeutics Corp REAGENTS AND METHODS FOR MODULATING DKK-MEDIATED INTERACTIONS
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP2135879A3 (en) * 2002-06-28 2010-06-23 Domantis Limited Ligand
EP1558646A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses thereof
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
WO2007027509A2 (en) 2005-08-31 2007-03-08 Biogen Idec Ma Inc. Evaluating and treating scleroderma
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CA2663042A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2097449A1 (en) 2006-12-05 2009-09-09 Ablynx N.V. Peptides capable of binding to serum proteins
AU2009221106A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン.ヴェー. 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
US8716243B2 (en) 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
EP4219545A1 (en) 2009-12-23 2023-08-02 Novartis AG Method for decreasing immunogenicity
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
EA201201227A1 (ru) 2010-03-03 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Бипаратопные а-бета-связывающие полипептиды
EP2550295A1 (en) * 2010-03-24 2013-01-30 F. Hoffmann-La Roche AG Anti-lrp6 antibodies
CA2798390A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP2566892B1 (en) * 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
AU2012211277A1 (en) * 2011-01-28 2013-08-29 The Board Of Trustees Of The Leland Stanford Junior University Wnt compositions and methods of use thereof
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
JP6258199B2 (ja) 2011-06-23 2018-01-10 アブリンクス エン.ヴェー. 免疫グロブリン単一可変ドメインを伴うアッセイにおける非特異的タンパク質干渉を予測、検出及び低減するための技術
UA118833C2 (uk) 2011-08-17 2019-03-25 Ґлаксо Ґруп Лімітед Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1
EP3290442A1 (en) 2011-11-04 2018-03-07 Novartis AG Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs
SG10201601747XA (en) * 2012-01-18 2016-04-28 Genentech Inc Anti-LRP5 Antibodies And Methods Of Use
UA122079C2 (uk) * 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6
MA48760A (fr) * 2017-05-31 2020-04-08 Boehringer Ingelheim Int Polypeptides ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales
CN113646048A (zh) * 2019-03-29 2021-11-12 勃林格殷格翰国际有限公司 抗癌组合疗法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017085172A2 (en) * 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Bryan T MacDonald et al., Dissecting molecular differences between Wnt coreceptors LRP5 and LRP6. PLoS One. 6(8): doi: 10.1371/journal.pone.0023537. Epub 2011 Aug 24. e23537. *
期刊 Seth A Ettenberg et al., Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci USA. 107(35): doi: 10.1073/pnas.1007428107. 2010 Aug 31; Epub 2010 Aug 16. 15473-15478.; *

Also Published As

Publication number Publication date
CN110637030A (zh) 2019-12-31
BR112019022729A2 (pt) 2020-05-19
US11033636B2 (en) 2021-06-15
EP3630816B1 (en) 2024-03-20
JP2020521478A (ja) 2020-07-27
AU2018276409A1 (en) 2019-10-31
CL2019003419A1 (es) 2020-03-27
PH12019502602A1 (en) 2020-06-08
PE20200610A1 (es) 2020-03-10
IL270854B2 (en) 2023-02-01
EA201992808A1 (ru) 2020-05-14
CA3060401A1 (en) 2018-12-06
US12285493B2 (en) 2025-04-29
KR20200011933A (ko) 2020-02-04
ZA201906610B (en) 2025-12-17
IL270854A (en) 2020-01-30
CO2019012329A2 (es) 2020-01-17
WO2018220080A1 (en) 2018-12-06
CN110637030B (zh) 2024-06-11
EP3630816A1 (en) 2020-04-08
ES2979194T3 (es) 2024-09-24
US20250345448A1 (en) 2025-11-13
KR102717656B1 (ko) 2024-10-14
MX2019014331A (es) 2020-01-27
JP7216024B2 (ja) 2023-01-31
UA125761C2 (uk) 2022-06-01
MA48760A (fr) 2020-04-08
IL270854B (en) 2022-10-01
TW201906858A (zh) 2019-02-16
AU2018276409B2 (en) 2025-02-27
MY200744A (en) 2024-01-13
AR111840A1 (es) 2019-08-21
EP3630816C0 (en) 2024-03-20
PL3630816T3 (pl) 2024-08-05
US20220362393A1 (en) 2022-11-17
US20180344868A1 (en) 2018-12-06
HUE067691T2 (hu) 2024-11-28

Similar Documents

Publication Publication Date Title
US11952418B2 (en) Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
TWI887192B (zh) 拮抗腫瘤細胞中wnt訊息傳導之多肽
HK40040630A (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
EA046752B1 (ru) Полипептиды, препятствующие передаче wnt сигналов в опухолевых клетках
HK1255725B (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
EA040170B1 (ru) БИПАРАТОПНЫЕ ПОЛИПЕПТИДЫ-АНТАГОНИСТЫ ПЕРЕДАЧИ СИГНАЛА Wnt В ОПУХОЛЕВЫХ КЛЕТКАХ